RecruitingPhase 3NCT07428499
Rare condition
Hereditary angioedema type 1
12
studies recruiting now
as of 7 Sept 2026
174
studies registered in total
as of 7 Sept 2026
37
countries with a recruiting site
as of 7 Sept 2026
23 Feb 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT07298447
Donidalorsen Treatment in Children With Hereditary Angioedema
RecruitingPhase 3NCT06679881
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
RecruitingNCT06210698
Angioedema Biomarker Research Study
RecruitingPhase 3NCT06361537
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 12 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Hereditary angioedema type 1 study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Hereditary angioedema type 1
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (SERPING1).
Treatments being studied
1 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2Feniralstat
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).